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Abstract
Growth in height is a multifactorial process in which 80–90% of the contributing factors
are genetic. The genes that determine the appropriate morphology and function of the
skeletal and endocrinal system are the most being involved. Short stature is a clinical
sign noted in conditions that  intrinsically affect  the growth plate,  such as skeletal
dysplasia, or in genetic syndromes such as Turner's, Silver‐Russell, Noonan's, Cornelia
de  Lange's,  Rubinstein‐Taybi  and  Prader‐Willi  syndrome.  Also,  some  endocrine
diseases or chronic disorders can lead to change growth in the plate physiology, leading
to short stature; the endocrine disorders are often genetically determined. Another
category is idiopathic short stature, which is the most important in terms of frequency,
and even though in this case, the aetiology is not proven; it seems that the genetic factors
have the main role. In this chapter, the genetic syndromes with primary effect on growth
are presented and the principal aim is to highlight the main clinical signs associated
with short stature, which can lead to an easier clinical diagnosis of a genetic disease that
mainly influence growth, thus facilitating the selection of the genetic test needed for the
etiologic diagnosis in short stature.
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1. Introduction
Growth is defined as elongation and maturation of the bones and is a multifactorial process;
more  than 80% of  growth is  contributed by  coordination  of  genetic  factors  [1].  Genetic
influence is argued by the height difference observed in different ethnic populations or in
different families. An argument for the role of environmental factors is done by the secular
trend of growth observed in the last 150 years and is usually correlated with a better socio‐
economic status [2].
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In order to understand the effect of genes on processes of growth, it is important to know about
‘major genes’ and ‘minor genes’ [3]. ‘The major genes’ have a critical role on growth, and single
mutations in them usually results in growth pathology (monogenic disorders) [3]. Mutations
of ‘the minor genes’ only provide a susceptibility for growth abnormalities (multifactorial
disorders) [3] whose effect being validated as a disease when multiple genetic and environ‐
mental factors act together.
A mutation of a ‘major gene’ (monogenic disease) is usually considered, when the short stature
is severe, under ‐3DS or when the short stature is associated with malformative syndrome or/
and dysmorphic features or/and intellectual disability or there is an evidence for skeletal
dysplasia or microcephaly or small for gestational age (SGA) without catch‐up growth or
severe growth hormone (GH) deficiency or multiple pituitary hormones deficits [4]. The
mutations of ‘minor genes’ are usually conducted to a growth phenotype that is only slightly
affected (familial or constitutional short stature), this effect being multifactorial determined.
Concerning ‘the minor genes’, the genome‐wide association studies (GWAS) demonstrated
that there are more than 180 genetic variants correlated with growth, on autosomes, with
independent, additional effect of 0.2–0.6 cm for every allele [5, 6]. Also, it was also observed
that there are two types of genes: ‘height genes’, having the main role in adult height, and
‘tempo genes’ , important for the starting moment of the different processes of growth [6, 7].
Genetic factors act mainly through skeletal and endocrine systems.
Short stature represents a height under ‐2DS for the average of general population of the same
age, sex and ethnicity. A useful classification of the aetiology in short stature divides it into
primary, secondary and idiopathic short statures.
Primary short stature includes intrinsic conditions of the growth plate (15–20% of cases) [8],
such as skeletal dysplasia, genetic syndromes (Turner, Down, DiGeorge, Silver‐Russell,
Noonan, Cornelia de Lange, Rubenstein‐Taybi, Prader‐Willi and neurofibromatosis type I) and
SGA with failure of catch‐up growth.
Secondary short stature refers to conditions that change growth plate physiology (30–35% of
cases) [8], such as endocrine disorders, chronic disorders in different organ and systems,
insufficient nutrient intake (malnutrition) and metabolic or psychosocial disorders.
Idiopathic short stature (50% of cases) [8] includes familial short stature, non‐familial short
stature and constitutional growth and puberty delay.
In every category, the genetic aetiology is obvious for a great number of disorders, especially
in primary short stature and endocrine disorders. Even in idiopathic short stature, it was
observed that in more than 20% of cases, there is a subtle skeletal dysplasia that is also
genetically determined [9], 4% of them were demonstrated to have short stature homeobox
(SHOX) gene deletion [10]. Also in familial idiopathic short stature, the genetic background is
evident.
In this chapter, the disorders included in the category primary short stature, where genetic
factors have a clearer contribution and where usually one major gene is implicated in the
processes of abnormal growth, will be mainly presented. In the genetic evaluation of a child
Restricted Growth - Clinical, Genetic and Molecular Aspects74
with short stature, ‘the major genes’ are usually searched, the others, such as ‘minor genes’,
give only a predisposition and are considered only after the exclusion of the major factors. An
adequate genetic evaluation usually facilitates decisions about therapeutic intervention and
gives clues about the prognosis.
2. Genetic disorders with primary effect on growth
2.1. Skeletal dysplasia
The specific clinical trait of the skeletal dysplasia is a disproportionate short stature, with
associated signs such as shorter and bowed long bones, shorter ribs, polydactyly, impaired
bone density and bone modelling, disorganized development of growth cartilage and
ossification defects. Growth retardation is seen in some skeletal dysplasia beginning with
intrauterine life or, for others, has a post‐natal onset in the first year of life or even later in some
cases. The diagnosis is usually established by clinical and radiological signs. Molecular
analysis for confirmation is required particularly in the situation of genetic counselling in order
to evaluate a future pregnancy by pre‐natal diagnosis. Otherwise, sometimes a skeletal
dysplasia can be diagnosed even for a patient with isolated short stature, apparently propor‐
tionate, whom only a radiological assessment may show the signs of dysplasia [9].
Skeletal dysplasia is a group of disorders, and is very heterogeneous; clinically and molecu‐
larly, more than 400 syndromes have been described, the more recent classification dividing
them into 40 principal groups [11]. Skeletal dysplasia without identified molecular bases is
also identified. In the following section, the most common and molecularly well‐characterized
skeletal dysplasia are presented.
2.1.1. The FGFR3‐related chondrodysplasias
The FGFR gene (4p16.3) encodes for fibroblast growth factor receptor 3 that has a main effect in
the regulation of chondrocyte proliferation, differentiation and apoptosis [12, 13]. FGFR3
regulates osteogenesis and post‐natal bone mineralization by osteoblasts, the main role being
in endochondral ossification [12, 13]. It has an extracellular region with three immunoglobulin‐
like domains, a transmembrane domain and an intracellular region with tyrosine kinase
domains. Mutations in FGFR3 gene lead to several syndromes with a phenotype more or less
severe according to the affected region of the receptor, such as achondroplasia, hypochondro‐
plasia, SADDAN syndrome (Severe Achondroplasia with Developmental Delay and Acan‐
thosis Nigricans) and thanatophoric dysplasia. The FGFR3 mutations responsible for these
syndromes are mutations with gain of function, inducing an activation of the receptor.
2.1.1.1. Achondroplasia
It is the most known form of disproportionate short stature and has a frequency of 1:25,000
births. In achondroplasia, FGFR3 gene mutations affect the transmembrane region of the
receptor [14]. Note that 98% of cases show G1138A mutation, an additional 1% of cases
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presenting the G1138C mutation [15, 16]. Achondroplasia is an autosomal dominant disorder
with complete penetrance. About 80% of cases occur as a result of de novo mutations, often
produced in paternal gametes, usually in case of an advanced paternal age at procreation [17].
These mutations are activating ones and affect mainly the endochondral ossification, with
impact on hypertrophic cellular compartment, chondrocyte proliferation in growth cartilages
and cartilage formation [12, 13].
Disproportionate short stature is a characteristic of the disease, adult height usually not
exceeding 125–130 cm. The clinical picture is represented by the specific skeletal features: short
rhizomelic limbs, relative macrocephaly, frontal bossing with mid‐face hypoplasia, trident
hands and hyperlordosis. The patients had associated with hypotonia (at young age) and
obesity (often in adults).
2.1.1.2. Hypochondroplasia
Hypochondroplasia is a pathology often produced by FGFR3 mutations in the extracellular or
intracellular region in the proximal tyrosine kinase domain [16]. In 70% of cases, FGFR3
mutations are described [18]. Some authors have noticed, in some cases, the association of
hypochondroplasia with IGF1 mutations [19]. There are some cases for which genetic deter‐
minant is not yet identified. Thus, unlike the achondroplasia, the hypochondroplasia is
characterised by genetic heterogeneity.
The clinical picture is that of a mild achondroplasia and is represented by disproportionate
short stature with short limbs but without an obvious rhizomelia, brachydactyly affected spine
by narrowing the interpediculate distance at the lumbar level [20]. Final height is not as
severely affected as in achondroplasia and is usually in the range 130–165 cm.
2.1.1.3. SADDAN syndrome
SADDAN syndrome is a severe form of achondroplasia associated with developmental
delay and acanthosis nigricans, the name of syndrome being an acronym of the main clinical
signs. In these disorders, a FGFR3 missense mutation Lys650Met was described, located at the
distal tyrosine kinase domain [21]. This mutation is located in the same codon as the specific
mutations that produce thanatophoric dysplasia.
Patients have bone dysplasia as described in achondroplasia, but more severe are important
short stature, micromelia, macrocephaly, frontal bossing, wide anterior fontanelle, mid‐face
hypoplasia, bowed tibia and narrow thorax [22]. In addition, they also have progressive
acanthosis nigricans, CNS abnormalities, epilepsy and severe developmental delay [21].
SADDAN syndrome clinically overlaps with thanatophoric dysplasia, but survival in the first
one is beyond the neo‐natal period, cases with this pathology are even reported in young
adulthood.
2.1.1.4. Thanatophoric dysplasia
It is the most common lethal skeletal dysplasia in the neo‐natal period. Two subtypes have
been described: thanatophoric dysplasia type I, caused by mutations in the extracellular or
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intracellular region of FGFR3 gene, and thanatophoric dysplasia type II, which is produced by
mutations at the distal tyrosine kinase domain [23, 24]. The most common mutation in type I
is R248C, confirmed in about 50% of the patients [24]. In type II, the K650E mutation is the only
one reported, which is present in more than 99% of the patients [23, 24].
The two forms of thanatophoric dysplasia were divided according to the clinical picture. In
type I, the clinical characteristics are the short and bowed long bones with skull normal
appearance [25, 26]. In type II, the traits are represented by the cloverleaf skull with short and
straight long bones [25]. Other associated signs, common to the two types are: platyspondyly,
narrow and short thorax, ventriculomegaly and polyhydramnios [25].
2.1.2. Disorders produced by abnormalities of collagen and other extracellular structural protein
2.1.2.1. Osteogenesis imperfecta
It occurs in 95% of cases due to COL1A1 (17q21.33) and COL1A2 (7q21.3) mutations, genes
encoding α1 and α2 polypeptide chains of type I collagen [27]. Type I collagen is the most
abundant collagen found in extracellular matrix protein and it is mainly present in cartilage,
bone, ligaments, tegument, dentin and sclera [28, 29]. Its role is structural, which interacts with
other matrix proteins (proteoglycans or fibronectins) and with the cells by anchoring them into
the matrix. A functional role was also described in signalling receptors on surface cells to
regulate cell growth, motility and differentiation [28–30].
The mutations of the chains of type I collagen lead to quantitative or qualitative impairment
and the clinical picture will be represented by the signs of the organs more abundant in type
I collagen: bones, articulations, dentin and sclera. These signs are multiple fractures arisen
usually after minor traumatisms, bone deformities, short stature, osteoporosis, joint hyper‐
laxity, dentinogenesis imperfecta, blues sclera, deafness and wormian bones. The skeletal
impairment is secondary to osseous fragility and osteopenia. Short stature is observed usually
secondary to the pathologic bone and its deformities. There are several clinical forms of
osteogenesis imperfecta, with different degree of severity. In 1979, Sillence and colleagues
described the four classical types of osteogenesis [31]. The actual classification includes fifteen
types, the first four being the known ones, produced by type I collagen mutations, the others
being the result of different gene mutations. Type I is a mild non‐deforming form of osteo‐
genesis imperfecta, with a blue sclera and a little or absent effect on growth. Type II is the most
severe form, lethal in the peri‐natal period. The clinical picture is represented by an important
osteopenia that leads to multiple fractures, secondary deformities and very short length from
the intrauterine period. Type III has also a severe phenotype, but less than the type II, repre‐
sented by very short stature, deformities, dentinogenesis imperfecta and blue sclera. Type IV has
an intermediate severity with a mild short stature, moderate deformities after recurrent
fractures, dentinogenesis imperfecta and normal sclera. If the chains of type I collagen are affected,
the transmission is autosomal dominant. In 5% of cases, osteogenesis imperfecta is secondary
to mutations of different genes, such as SERPINF1 (17p13.3), LEPRE1 (1p34.1), CRTAP (3p22),
PPIB (15q21‐q22), SERPINH1 (11q13.5), FKBP10 (17q21.2), SP7 (12q13.13), BMP1 (8p21.3),
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TMEM38B (9q31.2) and WNT1 (12q13.12); these disorders having an autosomal recessive
transmission, usually with a severe clinical phenotype [27].
2.1.2.2. Skeletal dysplasia in type II collagen abnormalities
Type II collagen is mostly found in cartilage, intervertebral disc and eye, and various mutations
lead to a group of diseases that have in common the abnormalities of epiphysis, spine and eyes,
which can easily be recognized by the signs in these structures [32]. The disorders of this group
of pathologies are specifically produced by different mutations of the same gene COL2A1
(12q13.11) that encodes for α1 chain of type II collagen [32]. The majority of COL2A1 mutations
were observed in the triple‐helical region of alpha 1 chain [33]. These disorders have an
autosomal dominant transmission. However, they are often produced by de novo mutations
and show a great variability of clinical expression.
2.1.2.2.1. Achondrogenesis
Achondrogenesis is one of the most severe skeletal dysplasia, with an important lethality, in
foetal life or in the neo‐natal period. There are two forms that differ by the type of transmission
(type I, recessive, and type II, dominant) and by the length and structure of long bones. The
clinical picture is characterized by very small length, extreme micromelia, very short trunk,
vertebral, skull and pelvis ossification defects, cupping metaphysis, cystic hygroma and
polyhydramnios [34]. Type II is secondary to neo‐mutations in type II collagen and is less
severe than achondrogenesis type I that is produced by TRIP11 or DTDST mutations. Achon‐
drogenesis type II is the most severe pathology of type II collagen group of disorders. Hypo‐
chondrogenesis represents a mild form of achondrogenesis type II and is also produced by
mutations in type II collagen [35].
2.1.2.2.2. Spondyloepiphyseal dysplasia congenita
It is characterized by poor somatic growth since intrauterine life. An important associated sign
is vertebral dysplasia, usually seen as platyspondyly. Other abnormalities often seen in this
disorder are cleft palate, ophthalmologic abnormalities (myopia, nystagmus, cataracts and
retinal detachment) and deafness. Short stature is also an important sign in the post‐natal
period, the height not exceeding 130 cm, other signs of skeletal dysplasia being deformation
of femoral head with a secondary coxa vara, scoliosis and impaired cervical spine [36]. There
is a significant clinical variability, the clinical spectrum including various forms of severity. The
responsible mutations that occur are missense mutations that substitute bulky amino acids for
glycine residues in the triple‐helical region of α1 chain of type II collagen [33].
2.1.2.2.3. Kniest dysplasia
Kniest dysplasia is characterized by extreme short stature, prominent joints, especially in knee,
and mid‐face hypoplasia. It is also associated with myopia, deafness or cleft palate. At vertebral
region, platyspondyly can be seen with vertical clefts, kyphoscoliosis or hyperlordosis [37].
Epiphysis is generally large, especially in the knee. The femoral head is often absent due to a
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developmental defect of the femoral epiphysis and the iliac bones are characteristically
shaped [37]. In Kniest dysplasia, the α1 chain of type II collagen is modified by exon skipping
due to splice‐site mutations in the region encoding the triple‐helical region [33].
2.1.2.2.4. Stickler dysplasia type I
Stickler dysplasia is characterized by genetic heterogeneity, the mutations in type II collagen
or type XI collagen being responsible for this pathology. The abnormalities of type II collagen
lead to Stickler dysplasia type I. The haploinsufficiency of truncation mutations that occur in
the triple‐helical region of α1 chain of type II collagen is responsible for the phenotype [33].
This syndrome also presents a clinical variability. The main clinical signs are represented by
skeletal and ophthalmologic disorders (high myopia and retinal detachment), auditory
abnormalities (deafness) and craniofacial dysmorphia (mid‐face hypoplasia, micrognathia,
midline cleft of the face and Pierre Robin sequence) [38, 39]. The patients usually present a
short stature associated with a moderate spondyloepiphyseal dysplasia [39]. Radiologic signs
are often minor, such as discreet flattening and irregularities at the epiphyseal region or a
minimum platyspondyly, especially in the dorsal region. Patients associate widening joints,
especially in the knee, and osteoarthritis with early onset [39].
2.1.2.3. Skeletal dysplasia in type IX collagen, cartilage oligomeric matrix protein (COMP) and matrilin
3 (MATN3) abnormalities
Type IX collagen, cartilage oligomeric matrix protein and matrilin 3 are components of the cartilage
extracellular matrix that strongly interacts to maintain cartilage assembly and integrity [40,
41]. A mutation of one of these components modifies the secretion of the others and the
common pathology produced for each gene mutation is multiple epiphyseal dysplasia (MED)
[41]. The pathogenesis is represented by the impairment of endochondral ossification due to
cartilage abnormalities.
There are six types of MED produced by mutations of COMP (19p13.1) (MED type I), COL9A2
(1p32.2–33) (MED type II), COL9A3 (20q13.3) (MED type III), DTDST (5q32–33) (MED type
IV), MATN3 (2p23–24) (MED type V) and COL9A1 (6q13) (MED type VI) [11]. With the
exception of MED type IV, all these disorders are transmitted in autosomal dominant manner.
All these types share a common clinical picture; some particularities being observed in each
type. The most specific signs of these disorders are short stature and precocious osteoarthritis.
Characteristically, the patients present pain and precocious fatigability when a physical
activity is initiated. The phenotypic signs are observed only post‐natally, after an apparently
normal initial development. Even if the skeletal impairment is generalized, the bones of inferior
limbs are more frequently involved, being often observed an angular deformation at this level,
such as coxa vara, genu varum, genu valgum and valgum deformities at the distal tibia.
The mutations of α1, α2 or α3 chain of type IX collagen (COL9A1, COL9A2, COL9A3) are
associated with a preponderant impairment of the knee [42].
In COMP mutations, the impairment of proximal femur and acetabulum is particularly
observed [43].
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In MATN3 mutations, the clinical picture is similar with that observed in COMP mutations,
but less severe [44].
2.1.2.4. Skeletal dysplasia in type X collagen abnormalities
Type X collagen also has an important role in endochondral ossification, influencing the
compartmentations of different matrix components and also the regulation of the mineraliza‐
tion [45].
2.1.2.4.1. Metaphyseal chondrodysplasia, Schmid type
It is produced by mutations of α1 chain of type X of collagen gene (COL1A10) (6q21–22.3), and
the transmission of the disorder is autosomal dominant. It is characterized by moderately short
stature with post‐natal onset, the size at birth being within normal limits. Radiography showed
irregularities in the metaphysis of long bones. The consequence of COL10A1 mutations is the
bowing and the shortening of the long bones, coxa vara being usually observed. Often, the
patients may develop the spine impairment, such as mild platyspondyly or other abnormalities
of the vertebral body.
2.1.2.5. Skeletal dysplasia in type XI collagen abnormalities
Type XI collagen has an important interaction with type II collagen, helping in maintaining
the spacing and the architecture of the type II collagen. Two polypeptide chains, α1 and α2,
contribute to the formation of type XI collagen; the genes that encode these chains being
COL11A1 (1p21) and COL11A2 (6p21.3). The mutations in these genes lead to a clinical
phenotype of skeletal dysplasia overlapping with that produced by type II collagen abnor‐
malities.
2.1.2.5.1. Stickler dysplasia type II
It is the consequence of COL11A1 mutations. These mutations lead to a clinical picture similar
to that described in Stickler syndrome type I (see Section 2.1.2.2.4), the main clinical signs being
the consequence of skeletal, ophthalmologic and auditory impairments. However, the clinical
severity is higher in terms of ophthalmologic (severe myopia, bilateral retinal detachment) and
auditory (deafness) phenotypes [46]. The craniofacial dysmorphic features that are specific for
Stickler syndrome type I or II are as follows: mid‐facial hypoplasia, midline clefting and
retromicrognatia (Pierre Robin syndrome). The short stature is also seen associated with hip
abnormalities, such as slipped capital femoral epiphysis and mild thoracolumbar spinal
abnormalities that often lead to scoliosis [47, 48]. The disease has an autosomal dominant
transmission.
2.1.2.5.2. Otospondylomegaepiphyseal dysplasia (OSMED syndrome)
This dysplasia is the consequence of COL11A2 mutations and is also called non‐ocular Stickler
dysplasia. The disease has an autosomal recessive transmission. Skeletal similarities with
Kniest dysplasia is noticed, but without ophthalmologic involvement. However, the hearing
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impairment is much more important. Thus, the clinical picture is represented by sensorineural
hearing loss, disproportionate short stature with micromelia, enlarged epiphyses and spine
abnormalities, and dysmorphic facial features [49].
2.1.2.6. Sulfation disorders group
In this group of disorders, the main gene mutated is DTDST (5q32–33) that encodes for sul‐
phate transporter SLC26A2 that influences the sulfation of proteoglycans in cartilage matrix
[50]. The pathologies of this group are autosomal recessives, in contrast to the previously
presented anomalies that are characterized by autosomal dominant inheritance. The disor‐
ders produced by DTDST mutations are diastrophic dysplasia, achondrogenesis type IB,
atelosteogenesis type II and MED type IV [11].
2.1.2.6.1. Diastrophic dysplasia
It is characterized by disproportionate growth retardation with micromelia, debuted in pre‐
natal period [51]. Progressively, after birth, multiple joint contractures occur, especially in the
shoulders, elbows, hip and interphalangeal joints [52]. At birth, the congenital club foot, the
hypoplasia of the first metacarpal, thumb subluxation or cervical subluxation is also noted.
Long bones are short and large [52]. There is a progressive scoliosis. Other specific features are
the cysts observed at the ear pavilion [52]. Radiographic findings are metaphyseal widening
and epiphyseal dysplasia.
2.1.2.7. Skeletal dysplasia in perlecan disorders
The perlecan is a heparan sulphate proteoglycan that acts as a co‐receptor for FGF2, thus having
a role in intercellular adhesion and in promoting cells proliferation and angiogenesis. The
mutations of gene encoding perlecan (PLC, 1q36–34) induce different skeletal disorders
transmitted by autosomal recessive mode: dyssegmental dysplasia, Silverman‐Handmaker
type; dyssegmental dysplasia, Rolland‐Desbuquois type; and Schwartz‐Jampel syndrome [11].
2.1.2.7.1. Dyssegmental dysplasias
They are represented by two disorders, Silverman‐Handmaker and Rolland‐Desbuquois,
which are the forms of neo‐natal short‐limbed dwarfism. Both are produced by different
mutations of the same gene, PLC. The Silverman‐Handmaker type is the most severe, being
lethal in peri‐natal period, compared to Rolland‐Desbuquois, which is less severe [53]. The
skeletal abnormalities are represented by vertebral segmentation associated with long bones
impairments that are shorter, larger and bowed [54]. The vertebral segmentation is observed
as marked differences in size and shape of vertebral bodies. A reduced joint mobility is often
associated. A cleft palate as well as the encephalocele was described.
2.1.2.7.2. Schwartz‐Jampel syndrome
It is characterized by short stature, myotonic myopathy, joint contractures, pectus carinatum,
kyphosis, coxa valga, myopia and blepharophimosis [55, 56]. Radiological abnormalities
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include platyspondyly, short long bones with metaphyseal widening, wide epiphysis of the
distal femur and tibia, and fragmented capital femoral epiphysis.
2.1.2.8. Skeletal dysplasia in aggrecan disorders
The aggrecan, also known as cartilage‐specific proteoglycan core protein (CSPCP), is a
chondroitin sulphate proteoglycan, the most abundant structural component in the cartilage.
It leads to a normal chondroskeletal morphogenesis and it also provides a hydrated gel
structure in articular cartilage that is important for its resistance [57]. Different mutations of
the gene that encodes for aggrecan, AGC1 (15q26), are responsible for different diseases:
spondyloepiphyseal dysplasia, Kimberley type; spondyloepimetaphyseal and metaphyseal
dysplasia, aggrecan type; and familial osteochondritis dissecans [11].
2.1.2.8.1. Spondyloepiphyseal dysplasia, Kimberley type
It leads to a proportionate short stature, osteoarthritis with early onset and sometimes to a
craniofacial dysmorphia [58]. It is also defined by platyspondyly, vertebral cleft, metaphyseal
widening, epiphyseal irregularities and flattening of femoral epiphysis. It is an autosomal
dominant pathology.
2.1.2.9. Skeletal disorders in transient receptor potential vanilloid 4 (TRPV4) abnormalities
Transient receptor potential vanilloid 4 (12q24.1) mediates calcium influx, late in osteoclast
differentiation, thus influencing bone resorption [59]. TRPV4 mutations produce not only
skeletal pathologies but also non‐skeletal (such as spinal muscular atrophy, Charcot‐Marie‐
Tooth disease). The skeletal disorders are transmitted in autosomal dominant mode and
include metatropic dysplasia; spondyloepimetaphyseal dysplasia, Maroteaux type; spondy‐
lometaphyseal dysplasia, Kozlowski type; brachyolmia; and familial digital arthropathy with
brachydactyly [11].
2.1.2.9.1. Metatropic dysplasia
It is a severe form of skeletal dysplasia, often lethal in the neo‐natal period, and is characterized
by important disproportionate short length in newborn with micromelia, wide metaphyses,
platyspondyly, severe kyphoscoliosis, iliac areas in halberd, and limitations and enlargements
of the joints [60].
2.1.3. Defects in intracellular structural proteins
2.1.3.1. Filamin group
Although these intracellular structural proteins are expressed in all cells, it has been observed
that their mutations often induce a very severe skeletal pathologic phenotype. The filamin A
and B are cytoskeleton proteins, their role being structural, in signal transduction, in transport
or in intracellular and extracellular communication. Their mutations lead to the absence of
some bones or to joint dislocations.
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2.1.3.1.1. Filamin A disorders
Mutations of filamin A gene (FLNA, Xq28) lead to dominant X‐linked disorders. These are:
frontometaphyseal dysplasia, otopalatodigital syndromes type I and type II, Melnick‐Needles
syndrome and terminal osseous dysplasia with pigmentary defects [11].
Frontometaphyseal dysplasia is characterized by skeletal dysplasia, urogenital abnormalities
and deafness. Otopalatodigital syndrome type I is characterized by auricular impairment, cleft
palate and mild skeletal damage. Type II shows a more pronounced skeletal clinical picture
associated with multiple internal malformations (brain, heart and digestive). The Melnick‐
Needles syndrome is the most severe disorder of filamin A group, being lethal, most often for
intrauterine life.
2.1.3.1.2. Filamin B disorders
Mutations of filamin B gene (FLNB, 3p14.3) lead to different disorders transmitted in autosomal
dominant (the majority) and recessive mode (spondylo‐carpal‐tarsal dysplasia). These
disorders are atelosteogenesis type I, atelosteogenesis type III, Larsen syndrome and spondy‐
locarpotarsal syndrome [11].
Many of these diseases are lethal in the early neo‐natal period. In spondylocarpotarsal
syndrome, spine fusions were observed. The fusions also implied the carpal and tarsal bones.
On the other hand, a hyperlaxity was observed in some joints.
2.1.4. Disorders associated with SHOX gene mutations
Short stature homeobox gene belongs to the paired homeobox family and is localized in the
pseudoautosomal region 1 (PAR1) of X (Xp22) and Y (Yp11.3) chromosomes. SHOX gene is
expressed in hypertrophic chondrocytes of the growth plate, having a role in regulating
chondrocyte differentiation [61, 62]. The diseases associated with SHOX gene abnormalities
are Leri‐Weill dyschondrosteosis (heterozygous mutations and deletions) and Langer meso‐
melic dysplasia (homozygous mutations). The skeletal features of Turner syndrome are also a
consequence of SHOX gene haploinsufficiency. Otherwise, SHOX gene mutations were
observed at 2–5% of patients with idiopathic isolated short stature [63–65].
SHOX gene is an important determinant of growth, SHOX deletions being associated with
short stature and SHOX duplications with tall stature. SHOX gene is expressed in the first and
second pharyngeal arches and also in elbow, radius, ulna, and wrist and in the equivalent bones
of inferior limbs [66]. Thus, the clinical picture in SHOX deficiency is represented by short
stature, mesomelia with shortening and bowing of the forearms and tibia, cubitus valgus,
Madelung deformity of the wrist, brachymetacarpia, brachymetatarsia, high‐arched palate,
micrognathia and short neck [67]. SHOX gene deficiency leads to a marked phenotypic
variability, even for the same mutation or in the same family. The clinical picture is more
expressed in females and is usually more evident in the beginning of the puberty [68].
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2.1.4.1. Leri‐Weill dyschondrosteosis
It is the most common form of mesomelic dysplasia and is characterized by disproportionate
short stature (145–155 cm) with mesomelia and Madelung deformity [67]. There is an impor‐
tant clinical variability, even in the same family, the females often being more affected. Short
stature is observed from the childhood, even from the first year and usually the amplitude of
the growth deficiency is correlated with the degree of wrist deformity [67]. The causes of Leri‐
Weill dyschondrosteosis are heterozygous mutations or deletions of SHOX gene.
2.1.4.2. Langer mesomelic dysplasia
It is secondary to homozygous mutations of SHOX gene and the clinical picture is represented
by severe short stature (‐6DS and ‐7DS) with severe abnormalities of the limbs: hypoplasia and
aplasia of the ulna and fibula [67].
2.2. Genetic syndromes with primary effect on growth
2.2.1. Turner syndrome
The Turner syndrome is due to complete or partial loss of one of the two sex chromosomes,
homogeneous or in mosaic, in a female patient. Only 50% of the cases present the classical
homogeneous monosomy 45,X, the other half having X chromosome mosaicism, X chromo‐
some structural abnormalities (deletions, ring chromosome and isochromosome) or Y chro‐
mosome abnormalities (2–5%). The phenotypic features are represented by short stature,
dysmorphic syndrome, gonadal dysgenesis and internal malformations. There is a great
variability of phenotypic traits, clinical spectrum including complete forms and more often
partial forms, represented sometimes only by short stature.
Short stature is the most constant clinical sign, observed in up to 98% of patients [69, 70]. It is
secondary to SHOX gene haploinsufficiency. The growth retardation might be seen in about
half of patients beginning with pre‐natal life [70]. In the others, the short stature will be
developed usually after the age of 3–4 years, due to a diminished velocity of growth. The
growth worsens progressively until 10 years and the lack of puberty growth spurt will
accentuate the deficit. Finally, height will be usually between the interval 122–147 cm [71].
The dysmorphias include triangular face, epicanthus, down‐slanted palpebral fissure,
macrostomy, high‐arched palate, dental abnormalities, micrognathia, low posterior hair
insertion line ‘in trident’, pterygium colli, large thorax, cubitus valgus, short IV and/or V
metacarpals, genu valgum, extremities lymphedema at birth, multiple pigmented nevi and
dysplastic nails [70].
The puberty delay is one of the most common signs being observed in up to 95% of cases [70].
Most patients with Turner syndrome show a normal intellectual development, excepting those
presenting ring X chromosome, who often present intellectual disability [72].
Cardiovascular malformations are particularly important in terms of evolution and prognosis,
being found in 25–40% of cases [69, 70]. The most specific cardiac abnormalities are bicuspid
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aortic valve and aortic coarctation. Reno‐urinary malformations are observed in 40–60% of the
cases, the most representative being horseshoe kidney, polycystic kidney, renal agenesis and
duplicated collecting system [71].
Bone abnormalities, affecting more than 60% of patients, have a significant contribution to the
external phenotype of the Turner syndrome. Typically, these patients present a lower value for
upper segment/lower segment ratio, short neck, large thorax, scoliosis, kyphosis, cubitus
valgus, Madelung deformity, congenital hip dislocation, genu valgum, and short IV and/or V
metacarpal and metatarsal [63, 70].
2.2.2. Russell‐Silver syndrome
It represents a genetic pathology in which the short stature is the most specific sign. It is very
heterogeneous in terms of genetic aetiology and in many cases (about 50%) with typical clinical
picture, the aetiology is unknown. Note that 40% of patients present hypomethylation of
imprinting centre 1 (IC1) (H19, 11p15) [73, 74]. This hypomethylation could occur by epigenetic
mechanisms or by duplications of maternal chromosome in 11p15 region. About 10% of
patients present maternal uniparental disomy of chromosome 7 [73]. There were reported cases
with 17q25 translocations, ring chromosome 2 or other structural abnormalities of 1, 15 or X
chromosomes that also had a clinical phenotype of Russell‐Silver syndrome [75–77].
The clinical picture is specifically represented by intrauterine growth retardation without
catch‐up growth in the first year of life [78]. This deficit is maintained or it gets even worse
over time, the adult height being lower than ‐3DS for average height. At birth, the weight is
more impaired than height. The head circumference is normal for age, being in contrast with
a lower height, thus the patient has an appearance of macrocephaly. The craniofacial dysmor‐
phias include triangular face, high forehead, micrognathia and down‐slanted oral commis‐
sures. The limbs are often asymmetrical and a clinodactyly or a camptodactyly of one (fifth
finger) or more fingers can be frequently observed. Eating difficulties in infancy, fasting
hypoglycemia in infancy and childhood, global developmental delay and cognitive impair‐
ments (at about 50% of patients) were also observed. Bone age is retarded, and the radiography
also shows a hypoplasia of middle phalanx of fifth finger, which give the appearance of
clinodactyly (observed in up to 80% of patients). Sometimes, the patients associate urogenital
(hypospadias) or cardiovascular malformations.
2.2.3. Noonan syndrome
This syndrome is very heterogeneous as aetiology, and usually, all the gene mutations
described are acting on the signal transduction pathway RAS/RAF/MEK/ERK that has a role
in regulating cell growth. About 50% of patients have mutations in PTPN11 gene [79]. An
additional percentage of 30% shows mutations in SOS1 gene and RAF1 gene. Other gene
mutations that lead to Noonan syndrome phenotype are KRAS, NRAS, BRAF and MAP2K1
[79].
The characteristic features of Noonan syndrome are short stature, craniofacial dysmorphic
features, cardiac malformation and thoracic deformity. Short stature has a post‐natal onset.
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The dysmorphias are represented by triangular face, down‐slanted palpebral fissure, hyper‐
telorism, low‐set ears and pterygium colli. Note that 80% of patients have cardiovascular
malformations. The most frequent is pulmonary artery stenosis. About 30% of patients may
present hypertrophic cardiomyopathy. Thorax deformation can be pectus excavatum or pectus
carinatum. The patients can associate cryptorchidism (50% of male patients), kidney abnor‐
malities, bleeding disorders, articular hyperlaxity, lymphedema, multiple nevi, hypotonia and
epilepsy. The intellectual disability is observed in about 25% of cases.
2.2.4. Cornelia de Lange syndrome
About 50% of patients with Cornelia de Lange syndrome show mutations in NIPBL gene [80].
Rarer mutations have been described for SMC1L1, SMC3 and RAD21 genes [80].
It is characterized by pre‐ and post‐natal growth retardation, characteristic craniofacial
dysmorphic features (narrow forehead with low hair insertion line, synophrys, nostrils
anteversion, prognathism, long philtrum, thin lips and down‐slanted oral commissures)
intellectual disability, upper limbs abnormalities and hypertrichosis. Male patients often
present hypospadias and cryptorchidism. Cardiovascular malformations, ophthalmologic
abnormalities, deafness, behaviour disorders, global developmental delay, epilepsy and
ophthalmologic abnormalities were described. There is a wide phenotypic variability of the
syndrome, even some cases with normal IQ have been described.
2.2.5. Rubinstein‐Taybi syndrome
This syndrome is also characterized by genetic heterogeneity: CREBBP mutation (30–50% of
cases), CREBBP deletion/ duplication (10–20%), 16p13.3 deletions (including CREBBP) (below
10%) and EP300 mutation (5%) [81].
Clinically, it is characterized by short stature with post‐natal onset, intellectual deficiency,
characteristic craniofacial dysmorphia (prominent beaked nose, downslanted palpebral
fissures, upper jaw hypoplasia, high arched palate, low‐set ears, thin superior lip, microce‐
phaly), and broad thumb with radial angulation, broad hallux, syndactyly, eating difficulties
and respiratory disorders in infancy. These patients associate language retardation, hypotonia,
cardiac malformations or cryptorchidism.
2.2.6. Prader‐Willi syndrome
The Prader‐Willi syndrome is the result of paternal loss of imprinted 15q11.2‐13 region. This
is produced through deletions (70% of cases), uniparental maternal disomy (28%), unbalanced
translocations (1%) or mutations in imprinting centre (1%) [82]. Several genes are located in
this region, whose function has been already associated with various phenotypic traits of
Prader‐Willi syndrome (SNRPN gene with brain expression, P gene with oculocutaneous
albinism and NDN gene with brain expression) [83].
Most of the clinical specific signs are due to hypothalamic impairment. The clinical presenta‐
tion is variable, depending on age. Infants with Prader‐Willi syndrome show generalized
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hypotonia, eating difficulties, males with genital abnormalities (cryptorchidism and scrotal
hypoplasia) and motor acquisition delays. After the age of 2, children progressively develop
obesity due to hyperphagia. A gradually slowdown in growth, the short stature being often
installed before pubertal age and accentuated thereafter by the lack of pubertal growth spurt
were also noticed. Most patients also have a deficiency of GH, for which a hormonal treatment
is proposed, which also ameliorate the associated metabolic abnormalities. The hypothalamic
involvement also induces a hypogonadotropic hypogonadism manifested by cryptorchidism
and hypospadias in males or delayed puberty in both sexes, which requires hormonal
substitution therapy. Often, the intellectual deficiency is mild. Lifespan is usually influenced
by the complications of morbid obesity, often seen in the patients with sleep apnoea, diabetes,
atherosclerosis and cardiovascular complications.
2.2.7. Kabuki syndrome
The genes involved in Kabuki syndrome are KDM6A (Xp11.3) and KMT2D (12q13.12) [84].
Clinically, it is characterized by short stature with post‐natal onset, global developmental
delay/intellectual disability, specific craniofacial dysmorphia (long palpebral fissures, ectro‐
pion in the third external region of the upper eyelid, sparse eyebrow in third external region,
flattening of the nasal pyramid, large and prominent ears, high arched palate and cleft palate),
scoliosis, fifth finger brachydactyly and persistence of finger pads. The associated skeletal
abnormalities are spine anomalies, often with vertebral cleft, hip joint abnormalities and fifth
finger brachydactyly. Cardiovascular malformations are associated in 50% of cases (Tetralogy
of Fallot, atrial septum defects or ventricular septum defects). The characteristic craniofacial
dysmorphias, post‐natal growth retardation and intellectual disability are among the cardinal
manifestations of the disease.
2.2.8. Williams syndrome
Williams syndrome is secondary to recurrent deletion in 7q11.23 region comprising elastin
gene (ELN).
The specific features are craniofacial dysmorphias, cardiovascular malformation, short stature,
neuropsychiatric and behavioural disorders, and idiopathic hypercalcemia [85]. Growth
retardation is observed in both pre‐natal and post‐natal periods. The patients often present a
delayed bone age and low levels of IGF1. Craniofacial phenotype is represented by stellate iris,
periorbital oedema, flattening of nasal pyramid, short nose with anteverted nostrils, long
philtrum, macrostomy, thick lips, microdontia, multiple diastema, dental malocclusion and
micrognathia. The specific cardiovascular malformation is represented by supravalvular aortic
stenosis, seen in more than 80% of patients. Other major arteries stenosis could also be seen.
Other frequent signs are hyperacusis, thick voice, articular hyperlaxity, kyphoscoliosis and
lordosis. Usually the intellectual disability is moderate, although sometimes, it can be very
severe and there are also cases described with IQ in the normal range. These children are
hypersociable and hyperactive with attention deficit, often characterized as having a ‘cocktail
party’ personality.
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3. Clinical and genetic evaluation in genetic short stature
3.1. Anamnestic data
3.1.1. Personal data
In face of a case with short stature, the anamnesis should be conducted in order to obtain the
personal information, normal and pathologic, related to
• Pre‐natal period: pre‐natal echography and data on pregnancy (possible incidents and
teratogen exposure).
• Peri‐natal period: data on birth (possible incidents, type of birth), auxology at birth (weight,
length, head circumference), gestational age and data on neo‐natal period.
• Infancy period: data on nutrition, auxology, psychomotor development and others inci‐
dents.
• Childhood period until the moment of evaluation: data on growth ‐ previous growth data
and growth charts (height, weight, head circumference, body mass index); puberty; age at
start of pubertal signs and development of these signs; psychosocial development—school
performance, or data on intellectual performance, psychologic and affective status, social
environment; nutrition: quantity and quality of different nutriments, particularly vitamin
D and calcium intake; and level of physical activities.
• Data on different diseases or treatment.
• History of short stature: time of onset (pre‐natal or post‐natal), data on evolution and
associated signs.
3.1.2. Familial data
The familial history is also very important, and the evaluation should obtain the data on
ethnicity, consanguinity, parental height, tempo of height and puberty for the parents,
reproductive history of parents and family, family history on growth disorders, familial short
stature, skeletal disorders, endocrine disorders and autoimmunity.
3.2. Physical exam
3.2.1. Growth data
In every evaluation of a patient with short stature, the information on actual auxology are
essential and include height, weight, head circumference, body mass index (also in standard
deviation to the average) and mid‐parental height. These values are put on the growth charts
to evaluate the growth pattern that is also compared to midparental height.
To evaluate if the short stature is proportionate or not, the upper‐to‐lower segment ratio and
the arm span will be evaluated. In order to see a possible Madelung deformation, the forearm
will also be analysed.
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3.2.2. Other associated signs
A detailed clinical exam, general and on different organs and systems, is necessary to be
associated with auxologic evaluation. At adolescence, the evaluation of the puberty signs
should always be attentively assessed.
There are some specific signs associated with short stature, which could give a rapid suggestion
for the aetiology and diagnosis (Table 1) [86].
Clinical signs Genetic syndromes
Craniofacial dysmorphy
Midline face abnormalities: hypotelorism,
midline clefting, single median incisor
‐Hypophysis abnormalities and GH deficiency
Facial asimetry ‐Russell Silver syndrome, 22q11.2 deletion
Elf face ‐Williams syndrome
Moon face ‐Hypercorticism
Synophrys and hypertrichosis ‐Cornelia de Lange syndrome
Short nose and anteverted nostrils ‐Smith‐Lemli‐Opitz syndrome
High arched palate ‐SHOX deletion, Turner syndrome, 22q11.2 deletion
Pterygium colli ‐Turner syndrome, Noonan syndrome
Tegument and adipose tissue abnormalities
Multiple nevi ‐Turner syndrome, Noonan syndrome
Morbid obesity ‐Prader Willi syndrome
Skeletal signs
Disproportionate short stature ‐Skeletal dysplasia
Limbs asymmetry ‐Russell‐Silver syndrome
Cubitus valgum ‐Turner syndrome
Madelung deformity ‐SHOX deletion, Turner syndrome
4th and/or 5th brachymetacarpia ‐SHOX deletion, Turner syndrome, pseudohypoparathyroidism
Broad thumb ‐Rubinstein‐Taybi syndrome
5th finger clinodactyly ‐Russell Silver syndrome
Cardio‐vascular malformation
Bicuspid aortic valve, aortic coarctation ‐Turner syndrome
Supravalvulary aortic stenosis ‐Williams syndrome
Pulmonary stenosis ‐Noonan syndrome
Urogenital malformation
Cryptorchidism ‐Prader Willi syndrome, Noonan syndrome, Rubinstein Taybi
syndrome
Micropenis ‐Prader Willi syndrome, congenital GH deficiency
Shawl scrotum ‐Aarskog syndrome
Table 1. Clinical signs indicating different genetic syndromes in patients with short stature [86].
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Clinical feature Skeletal dysplasia
Limbs
Rhizomelic shortening ‐achondroplasia, thanatophoric dysplasia, diastrophic dysplasia, spondyloepiphyseal
dysplasia (SED)
Mesomelic shortening ‐Langer mesomelic dysplasia
Acromelic shortening ‐acrodysostosis
Micromelia ‐achondrogenesis, Kniest dysplasia, dyssegmental dysplasia
Short trunk ‐Kniest syndrome, metatropic dysplasia, SED
Thorax/ribs
Long or narrow thorax ‐Metatropic dysplasia
Pear‐shaped chest ‐Thanatophoric dysplasia, short‐rib polydactyly syndrome
Radial ray defects ‐Cornelia de Lange syndrome
Polydactyly ‐Chondroectodermal dysplasia, short‐rib polydactyly
Hands and feet
Hitchhiker thumb ‐Diastrophic dysplasia
Clubfoot ‐Diastrophic dysplasia, Kniest dysplasia, OI
Nails
Hypoplastic nails ‐Chondroectodermal dysplasia
Joints
Multiple joint dislocations ‐Larsen and otopalatodigital syndrome
Long bone fractures ‐OI, hypophosphatasia, achondrogenesis type I
Skull
Macrocephaly ‐Achondroplasia, achondrogenesis, thanatophoric dysplasia
Craniosynostosis ‐Craniosynostosis syndromes, hypophosphatasia
Cloverleaf skull ‐Thanatophoric dysplasia, craniosynostosis
Caput membranaceum ‐Hypophosphatasia, osteogenesis imperfecta (OI)
Multiple wormian bones ‐Cleidocranial dysplasia, osteogenesis imperfecta
Eyes
Congenital cataract ‐Chondrodysplasia punctata
Myopia ‐Kniest dysplasia and spondyloepiphiseal dysplasia
Mouth
High arched/cleft palate ‐Kniest dysplasia, diastrophic dysplasia, metatropic dysplasia
Ears
Acute swelling of the pinnae ‐Diastrophic dysplasia
Heart
Atrial septal defect ‐Chondroectodermal dysplasia
Patent ductus arteriosus ‐Lethal short‐limbed skeletal dysplasias
Mental retardation
‐Genetic syndromes—Rubinstein‐Taybi syndrome
‐Cranium pathology—craniostenosis
‐Metabolic disorders—lysosomal storage diseases
Table 2. Clinical signs indicating different skeletal dysplasias in patients with short stature [87].
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If the patient presents skeletal dysplasia, some clinical signs could orient to the aetiology
(Table 2) [87].
3.3. Investigations
3.3.1. Imagistic investigations
When evaluating a child with short stature, an X‐ray of hand and fist is needed to assess bone
age and growth potential. In primary short stature, the bone age is usually not delayed,
compared to secondary or idiopathic short stature where a retarded bone age is observed. The
bone age is necessary to obtain the predicted height for one patient. This examination is also
indicated in parents, if they also have short stature and bone deformities.
If the patient shows clinical signs of skeletal dysplasia, supplementary radiographs are needed
to assess long bones, spine and skull, in particular, the forearm (AP), pelvic radiographs (AP),
radiographs of the knee (AP) and spine (AP, lateral). Thus, in disproportionate short stature,
the radiographs could bring important indicators to establish the diagnosis of the type of
skeletal dysplasia, according to the affected area.
Sometimes, at radiography, there are not significant skeletal changes, but even so it cannot rule
out skeletal dysplasia, radiological monitoring being required, with repeated radiographs,
which may change over time.
3.3.2. Laboratory analysis
Represent the first‐line tests indicated in patients with short stature, particularly not elucidated
by clinical signs. These analyses must always evaluate the most common causes responsible
for somatic developmental delay: anaemic syndrome (erythrocytes, haemoglobin, haematoc‐
rit, iron); inflammatory syndrome (erythrocyte sedimentation rate, leucocytes); kidney
function and bone metabolism abnormalities (creatinine, urea, sodium, potassium, calcium,
magnesium, phosphor and alkaline phosphatase); renal tubular acidosis (acid‐base balance);
other renal disorders (urinalysis); malabsorption syndrome (iron, ferritin, total protein and
albumin); celiac disease (IgA anti‐endomysium and anti‐transglutaminase, total IgA); hypo‐
thyroidism (TSH, T4 free); and growth hormone deficiency (IGF1).
3.4. Genetic testing
Genetic testing follows to the routine non‐specific laboratory analysis. It should be performed
after an informed consent for genetic testing is obtained. If all the routine tests are negative
and clinical examination is not suggestive for certain pathology, a karyotype to any female
patient with short stature is routinely indicated. For a male patient with isolated short stature,
there is no consensus on routine testing by karyotype; however, an argument in performing
the karyotype being to detect a possible syndrome 45,X/46,XY.
If there are no clinical, imagistic or laboratory suggestions for a specific disease, a whole
genome analysis of copy number variants by CGH array (array based comparative genomic
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hybridization) or SNP array (array based single nucleotide polymorphism genotyping) will
be indicated. When there is the possibility, an analysis based on massive parallel sequencing
technology that will evaluate the whole exome or a panel of genes well known to be implicated
in short stature will be proposed. The algorithm of a genetic evaluation in short stature is
described in Figure 1.
Figure 1. Algorithm for genetic testing in short stature [4, 88].
In a patient with isolated proportioned short stature, the most common causes are numeric
abnormalities of X chromosome, SHOX gene mutations, discrete skeletal dysplasia, endocrine
disorders, SGA without catch‐up growth, constitutional growth retardation and familial short
stature. Thus, the genetic testing should take into consideration these aspects.
The patients with SGA without catch‐up growth are a special category of patients with short
stature, usually proportioned. The majority of patients with SGA (90%) recuperate the deficit
by the age of 1, maximum 2 years. Still about 10% of these patients remain with somatic deficit.
Often, these patients present associated dysmorphic signs. The main syndromes that have to
be taken into consideration in this situation are Russell‐Silver syndrome, Bloom syndrome,
Nijmegan breakage syndrome, Cockayne syndrome, Dubowitz syndrome, deficit in IGF1,
resistance to IGF1, Kenny‐Caffey syndrome, Schimke dysplasia or Smith‐Lemli‐Opitz syn‐
drome [88].
4. Conclusions
Short stature is a strongly genetically determined pathology. The group of genetic disorders
with primary effect on growth is very heterogeneous and comprises two important categories
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of pathologies: skeletal dysplasia and different genetic syndromes with primary effect on
growth. Their diagnosis is often difficult, thus, knowledge of the main clinical signs of each
syndrome and the algorithm for clinical diagnosis and genetic testing will practically lead to
an easier clinical and etiologic diagnosis.
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